Fierce Biotech January 19, 2024
Conor Hale

Leadership at the FDA and the Centers for Medicare and Medicaid Services issued a joint statement to reiterate plans to increase the federal oversight of lab-developed tests, commonly known as LDTs.

Last September, the FDA published a long-expected proposal to bring those types of tests in line with how the agency treats other in vitro diagnostics, with a multi-year timeline that would phase in reviews and other regulatory requirements through 2028.

LDTs had originally been designated a lower-risk category, since they were comparatively less complex tests and typically produced in small volumes by individual laboratories, including many on an as-needed basis. However, LDTs and their uses have evolved in recent years—in both their technology and their nationwide commercial reach, according...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: CMS, FDA, Govt Agencies, Provider
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article